(Q33929477)

30 July 2017

1 reference

title

Promising approaches in acute leukemia (English)

1 reference

30 July 2017

1 reference

Cortes J

1

1 reference

30 July 2017

Kantarjian HM

series ordinal

2

1 reference

30 July 2017

publication date

1 February 2000

1 reference

Investigational New Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

57-82

1 reference

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

30 July 2017

cites work

1 reference

12 December 2020

Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia

1 reference

12 December 2020

Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice

1 reference

12 December 2020

Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors

1 reference

12 December 2020

Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity

1 reference

12 December 2020

Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia

1 reference

12 December 2020

Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study

1 reference

12 December 2020

High remission induction (traditional sino-western HOAP) regimen for acute nonlymphocytic leukemia

1 reference

12 December 2020

Effect of melphalan against self-renewal capacity of leukemic progenitors in acute myeloblastic leukemia

1 reference

12 December 2020

Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differentiation induced by the antileukemic drug Harringtonine

1 reference

12 December 2020

HIC1 hypermethylation is a late event in hematopoietic neoplasms

1 reference

12 December 2020

Use of cytokines in the treatment of acute myelocytic leukemia: a critical review

1 reference

12 December 2020

Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma

1 reference

12 December 2020

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

12 December 2020

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1 reference

12 December 2020

Phase I trial of homoharringtonine administered by prolonged continuous infusion

1 reference

12 December 2020

All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia

1 reference

12 December 2020

The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia

1 reference

12 December 2020

Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

1 reference

12 December 2020

Effects of interferon-alpha (IFN) on the expression of interleukin 1-beta (IL-1), interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF) in acute myeloid leukemia (AML) blasts

1 reference

12 December 2020

Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2

1 reference

12 December 2020

Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study

1 reference

12 December 2020

Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification,

1 reference

12 December 2020

High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia

1 reference

12 December 2020

The CAMPATH-1 antigen (CDw52)

1 reference

12 December 2020

Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.

1 reference

12 December 2020

Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines

1 reference

12 December 2020

Characterization of a human B lymphocyte-specific antigen.

1 reference

12 December 2020

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

1 reference

12 December 2020

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

1 reference

12 December 2020

Harringtonine, an inhibitor of initiation of protein biosynthesis

1 reference

12 December 2020

Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195

1 reference

12 December 2020

Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes

1 reference

12 December 2020

Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression

1 reference

12 December 2020

Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

1 reference

12 December 2020

A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia

1 reference

12 December 2020

B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Lymphokine-activated killer cell plus recombinant interleukin-2 therapy of erythroleukemia in mice.

1 reference

12 December 2020

Tallimustine in advanced previously untreated colorectal cancer, a phase II study

1 reference

12 December 2020

Regulation of the synthesis of bcl-2 protein by growth factors

1 reference

12 December 2020

Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study

1 reference

12 December 2020

Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

12 December 2020

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

1 reference

12 December 2020

DNA topoisomerase poisons as antitumor drugs

1 reference

12 December 2020

Acute promyelocytic leukemia: a 5-year experience with new antileukemic agents and a new approach to preventing fatal hemorrhage

1 reference

12 December 2020

High-dose mercaptopurine and intermediate-dose cytarabine during first remission of acute myeloid leukemia

1 reference

12 December 2020

In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins

1 reference

12 December 2020

Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study

1 reference

12 December 2020

Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study

1 reference

12 December 2020

Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.

1 reference

12 December 2020

Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.

1 reference

12 December 2020

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1 reference

12 December 2020

Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo

1 reference

12 December 2020

Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia

1 reference

12 December 2020

Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis

1 reference

12 December 2020

5-Azacytidine in Refractory Acute Leukemia

1 reference

12 December 2020

Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin

1 reference

12 December 2020

Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines

1 reference

12 December 2020

Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model

1 reference

12 December 2020

Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response

1 reference

12 December 2020

Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia

1 reference

12 December 2020

Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours

1 reference

12 December 2020

Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195

1 reference

12 December 2020

R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate

1 reference

12 December 2020

Phase II study of roquinimex in myelodysplastic syndrome

1 reference

12 December 2020

Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units

1 reference

12 December 2020

The biology and treatment of acute lymphoblastic leukemia in adults.

1 reference

12 December 2020

Carboplatin infusion in relapsed and refractory acute myeloid leukemia--a Southwest Oncology Group trial

1 reference

12 December 2020

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1 reference

12 December 2020

FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.

1 reference

12 December 2020

Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells

1 reference

12 December 2020

Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement

1 reference

12 December 2020

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

12 December 2020

Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia

1 reference

12 December 2020

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

1 reference

12 December 2020

Effects of CPT-11 in combination with other anti-cancer agents in culture

1 reference

12 December 2020

Inhibitors of Ras farnesyltransferases

1 reference

12 December 2020

Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells

1 reference

12 December 2020

Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia

1 reference

12 December 2020

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

1 reference

12 December 2020

Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.

1 reference

12 December 2020

CD34+/CD33- cells reselected from macrophage inflammatory protein 1 alpha+interleukin-3--supplemented "stroma-noncontact" cultures are highly enriched for long-term bone marrow culture initiating cells

1 reference

12 December 2020

Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias

1 reference

12 December 2020

Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia

1 reference

12 December 2020

Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells.

1 reference

12 December 2020

Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine).

1 reference

12 December 2020

A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission

1 reference

12 December 2020

5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends

1 reference

12 December 2020

Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia?

1 reference

12 December 2020

Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission

1 reference

12 December 2020

MDR1 gene expression and treatment outcome in acute myeloid leukemia.

1 reference

12 December 2020

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

1 reference

12 December 2020

Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.

1 reference

12 December 2020

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

1 reference

12 December 2020

Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines

1 reference

12 December 2020

Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level

1 reference

12 December 2020

Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy

1 reference

12 December 2020

Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

1 reference

12 December 2020

Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2

1 reference

12 December 2020

Phase I study of liposomal daunorubicin in patients with acute leukemia

1 reference

12 December 2020

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype

1 reference

12 December 2020

The drug resistance-related protein LRP is the human major vault protein

1 reference

12 December 2020

Autografting in chronic myelogenous leukemia followed by immunotherapy

1 reference

12 December 2020

Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome

1 reference

12 December 2020

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

12 December 2020

FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia

1 reference

12 December 2020

The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.

1 reference

12 December 2020

Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells

1 reference

12 December 2020

Induction of apoptosis by gemcitabine

1 reference

12 December 2020

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

12 December 2020

Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells

1 reference

12 December 2020

Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression

1 reference

12 December 2020

Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.

1 reference

12 December 2020

Intravenous mercaptopurine: life begins at 40.

1 reference

12 December 2020

Biology of acute leukaemia

1 reference

12 December 2020

Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion

1 reference

12 December 2020

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

12 December 2020

Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells

1 reference

12 December 2020

Roquinimex-induced graft-versus-host reaction after autologous bone marrow transplantation

1 reference

12 December 2020

Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells.

1 reference

12 December 2020

Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor

1 reference

12 December 2020

Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells

1 reference

12 December 2020

Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL)

1 reference

12 December 2020

Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity

1 reference

12 December 2020

Phase I clinical investigation of homoharringtonine

1 reference

12 December 2020

Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia

1 reference

12 December 2020

Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases

1 reference

12 December 2020

The first clinical pilot study of roquinimex (Linomide) in cancer patients with special focus on immunological effects

1 reference

12 December 2020

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

12 December 2020

Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

1 reference

12 December 2020

CPT-11: clinical experience in phase I studies.

1 reference

12 December 2020

Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia

1 reference

12 December 2020

Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.

1 reference

12 December 2020

The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors

1 reference

12 December 2020

Liposomes as carriers of cancer chemotherapy. Current status and future prospects

1 reference

12 December 2020

Homoharringtonine: a phase I evaluation

1 reference

12 December 2020

Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833.

1 reference

12 December 2020

Treatment of acute myelogenous leukemia and myelodysplastic syndromes

1 reference

12 December 2020

Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study

1 reference

12 December 2020

Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner

1 reference

12 December 2020

Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies

1 reference

12 December 2020

Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia

1 reference

12 December 2020

Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

1 reference

12 December 2020

Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML

1 reference

12 December 2020

Mechanism of action of the new immunomodulator LS2616 on T cell responses

1 reference

12 December 2020

DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin

1 reference

12 December 2020

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

12 December 2020

Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.

1 reference

12 December 2020

Phase II clinical trial of carboplatin in relapsed and refractory leukemia

1 reference

12 December 2020

Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.

1 reference

12 December 2020

Treatment and prognostic factors in acute myeloid leukaemia

1 reference

12 December 2020

Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy

1 reference

12 December 2020

Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs

1 reference

12 December 2020

Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias

1 reference

12 December 2020

In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival

1 reference

12 December 2020

Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses

1 reference

12 December 2020

Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults

1 reference

12 December 2020

Response of therapy-related myelodysplasia to low-dose interleukin-2

1 reference

12 December 2020

Treatment of refractory undifferentiated acute myelogenous leukemia with all-trans-retinoic acid

1 reference

12 December 2020

The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia

1 reference

12 December 2020

A study on the induction of differentiation of human leukemic cells by harringtonine combined with cytarabine

1 reference

12 December 2020

Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia

1 reference

12 December 2020

Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology

1 reference

12 December 2020

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

1 reference

12 December 2020

A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893)

1 reference

12 December 2020

Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines

1 reference

12 December 2020

Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells

1 reference

12 December 2020

RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes

1 reference

12 December 2020

SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia

1 reference

12 December 2020

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

1 reference

12 December 2020

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

1 reference

12 December 2020

Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia.

1 reference

12 December 2020

Phase I study of liposomal vincristine

1 reference

12 December 2020

Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation

1 reference

12 December 2020

CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins

1 reference

12 December 2020

Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272)

1 reference

12 December 2020

Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia

1 reference

12 December 2020

2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia

1 reference

12 December 2020

The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing

1 reference

12 December 2020

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

1 reference

12 December 2020

Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

1 reference

12 December 2020

Small-dose Harringtonine induces complete remission in patients with acute promyelocytic leukemia

1 reference

12 December 2020

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study

1 reference

12 December 2020

Interleukin-2 therapy for myelodysplastic syndrome: does it work?

1 reference

12 December 2020

Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.

1 reference

12 December 2020

Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

1 reference

12 December 2020

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia

1 reference

12 December 2020

Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia

1 reference

12 December 2020

Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study

1 reference

12 December 2020

Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model

1 reference

12 December 2020

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without gran

1 reference

12 December 2020

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

12 December 2020

Dendritic cells and the control of immunity

1 reference

12 December 2020

Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia

1 reference

12 December 2020

In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.

1 reference

12 December 2020

9-cis-retinoic acid: effects on normal and leukemic hematopoiesis in vitro

1 reference

12 December 2020

Interleukin 2 in the management of acute leukaemia

1 reference

12 December 2020

Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide

1 reference

12 December 2020

Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides

1 reference

12 December 2020

Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study.

1 reference

12 December 2020

Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology

1 reference

12 December 2020

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients

1 reference

12 December 2020

Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemic cells from acute myelogenous leukemia patients treated with recombinant leukocyte-alpha A interferon

1 reference

12 December 2020

Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models

1 reference

12 December 2020

Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line

1 reference

12 December 2020

Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes

1 reference

12 December 2020

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

1 reference

12 December 2020

Studies of decitabine with allogeneic progenitor cell transplantation

1 reference

12 December 2020

Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.

1 reference

12 December 2020

Harringtonine in acute leukemias. Clinical analysis of 31 cases

1 reference

12 December 2020

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study

1 reference

12 December 2020

NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites

1 reference

12 December 2020

Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors

1 reference

12 December 2020

Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.

1 reference

12 December 2020

Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.

1 reference

12 December 2020

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).

1 reference

12 December 2020

Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study

1 reference

12 December 2020

Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia

1 reference

12 December 2020

Dexverapamil as resistance modifier in acute myeloid leukaemia.

1 reference

12 December 2020

Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions

1 reference

12 December 2020

Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan

1 reference

12 December 2020

Phase I study of the novel distamycin derivative tallimustine (FCE 24517)

1 reference

12 December 2020

Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells.

1 reference

12 December 2020

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

12 December 2020

A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

1 reference

12 December 2020

Cytosine arabinoside (Ara-C) plus alpha-interferon (alpha IFN) determine prolonged complete remissions in patients with aggressive non-Hodgkin's lymphoma partially responsive to first-line doxorubicin-containing regimens

1 reference

12 December 2020

Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy

1 reference

12 December 2020

Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia.

1 reference

12 December 2020

Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.

1 reference

12 December 2020

Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines

1 reference

12 December 2020

Potentiation of lysis of leukaemia cells by a bispecific antibody to CD33 and CD16 (Fc gamma RIII) expressed by human natural killer (NK) cells.

1 reference

12 December 2020

Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex

1 reference

12 December 2020

Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications

1 reference

12 December 2020

Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion

1 reference

12 December 2020

Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.

1 reference

12 December 2020

Phase I trial of homoharringtonine administered as a 5-day continuous infusion.

1 reference

12 December 2020

Sensitivity to 5-azacytidine of blast progenitors in acute myeloblastic leukemia.

1 reference

12 December 2020

Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.

1 reference

12 December 2020

CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment

1 reference

12 December 2020

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

12 December 2020

CI-973, a new platinum derivative with potential antileukemic activity

1 reference

12 December 2020

Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia

1 reference

12 December 2020

Comparative effects of busulfan, cytosine arabinoside and adriamycin on different maturation stages of normal human bone marrow cells

1 reference

12 December 2020

An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use

1 reference

12 December 2020

Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes

1 reference

12 December 2020

Effect of interleukin-1, tumor necrosis factor-alpha, and interferon-alpha on the blast cells of acute myeloblastic leukemia.

1 reference

12 December 2020

Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations

1 reference

12 December 2020

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006392116024

1 reference

Dimensions Publication ID

30 July 2017

1033517142

0 references

1 reference